Jianzhong Deng

Changzhou, 213017, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

GTPBP4 promotes colorectal cancer cell proliferation by positively regulating MYC-driven glycolytic metabolism.

GTPBP4 promotes colorectal cancer cell proliferation by positively regulating MYC-driven glycolytic metabolism.

Journal: American journal of cancer research

Published: April 10, 2026

FKBP9 Enhances Colon Cancer Cell Proliferation by Inhibiting GPX4-Mediated Ferroptosis.

FKBP9 Enhances Colon Cancer Cell Proliferation by Inhibiting GPX4-Mediated Ferroptosis.

Journal: Cancer medicine

Published: August 27, 2025

SLC41A2 Suppresses Colon Cancer Progression by Inhibiting GSK3β Ubiquitin-proteasome Degradation.

SLC41A2 Suppresses Colon Cancer Progression by Inhibiting GSK3β Ubiquitin-proteasome Degradation.

Journal: Current molecular medicine

Published: March 25, 2025

NKD1 enhances colon cancer progression by inhibiting the autophagic degradation of MYC.

NKD1 enhances colon cancer progression by inhibiting the autophagic degradation of MYC.

Journal: Cell death & disease

Published: November 01, 2024

Identification of HES4 as a novel prognostic marker and therapeutic target in hepatocellular carcinoma.

Identification of HES4 as a novel prognostic marker and therapeutic target in hepatocellular carcinoma.

Journal: Discover oncology

Published: July 18, 2024

Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.

Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.

Journal: Cancer immunology, immunotherapy : CII

Published: January 25, 2024

Identification and validation of a new pyroptosis-associated lncRNA signature to predict survival outcomes, immunological responses and drug sensitivity in patients with gastric cancer.

Identification and validation of a new pyroptosis-associated lncRNA signature to predict survival outcomes, immunological responses and drug sensitivity in patients with gastric cancer.

Journal: Mathematical biosciences and engineering : MBE

Published: March 11, 2023

Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report.

Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report.

Journal: Anti-cancer drugs

Published: February 02, 2023

m6A‑mediated LINC02038 inhibits colorectal cancer progression via regulation of the FAM172A/PI3K/AKT pathway via competitive binding with miR‑552‑5p.

m6A‑mediated LINC02038 inhibits colorectal cancer progression via regulation of the FAM172A/PI3K/AKT pathway via competitive binding with miR‑552‑5p.

Journal: International journal of oncology

Published: January 31, 2023

LncRNA OTUD6B-AS1 overexpression promoted GPX4-mediated ferroptosis to suppress radioresistance in colorectal cancer.

LncRNA OTUD6B-AS1 overexpression promoted GPX4-mediated ferroptosis to suppress radioresistance in colorectal cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 18, 2022

Let-7b-5p inhibits colon cancer progression by prohibiting APC ubiquitination degradation and the Wnt pathway by targeting NKD1.

Let-7b-5p inhibits colon cancer progression by prohibiting APC ubiquitination degradation and the Wnt pathway by targeting NKD1.

Journal: Cancer science

Published: September 01, 2022

M6A Promotes Colorectal Cancer Progression via Regulating the miR-27a-3p/BTG2 Pathway.

M6A Promotes Colorectal Cancer Progression via Regulating the miR-27a-3p/BTG2 Pathway.

Journal: Journal of oncology

Published: August 30, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026